LPC-233

Class: Lipopolysaccharide synthesis inhibitor

Spectrum of activity:	Gram-negative
Details of activity:	Active against Pseudomonas aeruginosa LpxC
Description:	No detectable adverse cardiovascular toxicity in dogs at 100 milligrams per kilogram; in preclinical evaluation
Year first mentioned:	2023
Development status:	Preclinical evaluation

Chemical structure(s):
Canonical SMILES:	C[C@]([C@@H](C(=O)NO)NC(=O)C1=CC=C(C#CC#CC2CC2)C=C1)(C(F)F)O
Isomeric SMILES:	C[C@]([C@@H](C(=O)NO)NC(=O)C1=CC=C(C#CC#CC2CC2)C=C1)(C(F)F)O
InChI:	InChI=1S/C19H18F2N2O4/c1-19(26,18(20)21)15(17(25)23-27)22-16(24)14-10-8-13(9-11-14)5-3-2-4-12-6-7-12/h8-12,15,18,26-27H,6-7H2,1H3,(H,22,24)(H,23,25)/t15-,19+/m1/s1
InChI Key:	NPTNDHDCCLLFJE-BEFAXECRSA-N

External links:
Guide to Pharmacology:	LPC-233
Main Source:	https://www.science.org/doi/10.1126/scitranslmed.adf5668